Article Versions Notes

Day WG, Heald J, Grigsby S, Beale P, Pittman L, DeStefano CB. Management of Secondary Immunodeficiency Following T-Cell-Engaging Immunotherapeutic Agents in B-Cell Non-Hodgkin Lymphoma: Implications for Early-Line Treatment Strategies. Lymphatics. 2024; 2(4):244-259. https://doi.org/10.3390/lymphatics2040019

Day, William Grant, Jon Heald, Sierrah Grigsby, Peter Beale, Luke Pittman, and Christin B. DeStefano. 2024. "Management of Secondary Immunodeficiency Following T-Cell-Engaging Immunotherapeutic Agents in B-Cell Non-Hodgkin Lymphoma: Implications for Early-Line Treatment Strategies" Lymphatics 2, no. 4: 244-259. https://doi.org/10.3390/lymphatics2040019

Day, W. G., Heald, J., Grigsby, S., Beale, P., Pittman, L., & DeStefano, C. B. (2024). Management of Secondary Immunodeficiency Following T-Cell-Engaging Immunotherapeutic Agents in B-Cell Non-Hodgkin Lymphoma: Implications for Early-Line Treatment Strategies. Lymphatics, 2(4), 244-259. https://doi.org/10.3390/lymphatics2040019